| Identification | Back Directory | [Name]
Ethyl 4-(2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl)piperazine-1-carboxylate | [CAS]
902589-96-2 | [Synonyms]
YMU1
Thymidylate Kinase Inhibitor, YMU1
Thymidylate Kinase Inhibitor, YMU1 - CAS 902589-96-2 - Calbiochem
Ethyl 4-(2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl)piperazine-1-carboxylate
4-[2-(4,6-Dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl]-1-piperazinecarboxylic acid ethyl ester
1-Piperazinecarboxylic acid, 4-[2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl]-, ethyl ester | [Molecular Formula]
C17H22N4O4S | [MDL Number]
MFCD27952931 | [MOL File]
902589-96-2.mol | [Molecular Weight]
378.45 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble1mg/mL, clear (warmed) | [form ]
White solid | [color ]
white to light brown | [InChI]
1S/C17H22N4O4S/c1-4-25-17(24)20-7-5-19(6-8-20)13(22)10-21-16(23)14-11(2)9-12(3)18-15(14)26-21/h9H,4-8,10H2,1-3H3 | [InChIKey]
XXUFNNVFZFVKGP-UHFFFAOYSA-N | [SMILES]
[s]1[n]([c](c3c1nc(cc3C)C)=O)CC(=O)N2CCN(CC2)C(=O)OCC |
| Hazard Information | Back Directory | [Uses]
YMU1 is a potent, reversible, and ATP-competitive inhibitor of human Thymidylate kinase (TMPK). | [Biological Activity]
YMU1 is a cell-permeable and nontoxic inhibitor of hTMPK (thymidylate kinase) th at sensitizes tumor cells to doxorubicin in vitro and in vivo. | [in vivo]
YMU1 (5 mg/kg, intraperitoneal injection, three times a week, for 25 days) and doxorubicin co-administered to mice inhibits tumor growth[1].
YMU1 (3-10 mg/kg, intraperitoneal injection, once every two days, for 30 days) inhibits the growth of A549 xenograft tumors in mice[2]. | Animal Model: | HCT-116 p53-/- cell transplantation model in nude mice[1] | | Dosage: | 5 mg/kg; 3 times a week; 25 days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Showed that tumors grew significantly slower in mice treated with doxorubicin. |
| Animal Model: | A549 nude mouse transplantation model[2] | | Dosage: | 3,10 mg/kg; once every two days; 30 days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced tumor volume and weight in a dose-dependent manner. |
| [IC 50]
STAT3 |
|
| Company Name: |
Lynnchem
|
| Tel: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
|